chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Chronic back and joint pain, growth of bone spurs on vertebrae, loss of memory, cognitive difficulties, chronic diarrhea, sleep disorder, depression, tremors, headaches, degenerative arthritis, poor balance, sub-clinical hyperthyroidism, muscle spasms. Per follow up report received on 06/09/2005:  Patient still has all of the symptoms listed above.
approx 12 hr p/vax & having recv APAP pt devel urticaria rash to upper extremities & swelling to upper lip & eyelids; no resp problems no fever; neurological tx; exam nl;
PT RECEIVED FLUZONE AND WITHIN MINUTES POST VACCINATION - MOTHER SAID INJECTION SITE WAS ITCHY AND SWOLLEN - NO OTHER SYMPTOMS, NO SOB, JUST LOCALIZED SWELLING - GIVEN ONE ORAL DOSE BENADRYL FOR CHILDREN AND APPLIED COLD PACK AT LEFT DELTOID - PT AND MOTHER LEFT AT 1230 AFTER 30 MINUTES OBSERVATION; FOLLOWED UP TODAY AROUND 6:15PM - FATHER SAID ITCHING AND REDNESS ARE GONE - NO OTHER SYMPTOMS
COVID arm since 2/15/21 am. Warmth, localized redness around injection site, swelling and tenderness.
Information has been received regarding a case in litigation. A female consumer reported that her 14 year old daughter who on an unspecified dates were vaccinated with three doses of GARDASIL. The patient's mother reported that the patient started having stomach pains since then. It was also reported that the patient was having continually urinary track infection, diarrhea and pains. At the time of this report, the patient's symptoms persisted. She sought unspecified medical attention. this is one of several reports received from the same source. Additional information has been requested. 11/24/08-records received-10/31/07-presented with C/O social issues. Now in adoptive home. 4/14/08-C/O sore throat, mild nasal discharge. Upper viral infection. 8/6/08-seen for school exam.
SWEATING; ACHES; CHILLS; FEVER; HEADACHE; This spontaneous report received from a consumer concerned a 54 year old male. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, and batch number: 1808982 expiry: UNKNOWN) dose was not reported, administered on 10-APR-2021 13:15 for prophylactic vaccination. No concomitant medications were reported. On 10-APR-2021, the subject experienced sweating. On 10-APR-2021, the subject experienced aches. On 10-APR-2021, the subject experienced chills. On 10-APR-2021, the subject experienced fever. On 10-APR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from fever, headache, chills, aches, and sweating. This report was non-serious. This case, from the same reporter is linked to 20210421450.
Two weeks after I had the first injection in my left arm where I had the injection had a severe red rash. The rash does not hurt or itch but it does have some heat to it.
feeling discomfort and pain in the arm where he had the shot; feeling discomfort and pain in the arm where he had the shot; This is a spontaneous report from a contactable consumer or other non hcp (Patient).    A 44-years-old male patient received bnt162b2 (BNT162B2), dose 1 at 11:37 am via an unspecified route of administration and unspecified date (Batch/Lot number was not reported) as single dose for covid-19 immunisation. Second dose was scheduled for 12May2021. The patient medical history and concomitant was not reported. On an unspecified date, after first dose he started feeling discomfort and pain in the arm where he had the shot, and took 2 Tylenol at 2:45 pm. The outcome of the events was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained
Pain radiation from injection site up are to shoulder blades down spine Extreme sweats and cold chills 102.2 fever off and on for 3 days Extremely weak and tired from Monday first night of first dosage until almost Saturday 5 days later
Pt received vaccination on 7/17/01 and on 7/23 developed fever to 101.5 with strange behavior. She was babbling, moving hands around, and seemed to fall down more than usual. Parents concerned. On 7/28 fever was to 103, and cranky. Pt was somewhat better the next 2 days. Seen in office 7/27. Pt had normal active behavior, tms dull, otherwise all WNL.
developing allergy to food; Fever; Fatigue; Malaise; Chills; Sweats; constant clenching of the jaw; Nausea; Loss of appetite; This case was reported by a consumer via call center representative and described the occurrence of fever in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of no adverse event (received 1st dose on an unknown date with no adverse event).   On 16th January 2020 14:10, the patient received the 2nd dose of Shingrix. In January 2020, 12 hrs 20 min after receiving Shingrix, the patient experienced fever, fatigue, malaise, chills, sweating, bruxism, nausea, appetite lost and food allergy. On an unknown date, the outcome of the fever, fatigue, malaise, chills, sweating, bruxism, nausea and appetite lost were recovered/resolved and the outcome of the food allergy was not recovered/not resolved.   It was unknown if the reporter considered the fever, fatigue, malaise, chills, sweating, bruxism, nausea, appetite lost and food allergy to be related to Shingrix.  Additional details were provided as follows: The reporter was the patient. The patient received 2nd dose of Shingrix in right arm. The patient received dose of Shingrix on 16th January 2020 at 2:10pm  and on 17th January 2020 at 2:30am experienced fever of 102.6, fatigue, malaise, chills, sweats, a constant clenching of the jaw, nausea, and loss of appetite. The patient reported that, all of the symptoms began simultaneously and all of these symptoms subsided 3 days later. The patient reported developing an allergy to all food items except corn, rice, and chicken within a week to 10 days of receiving the second dose of Shingrix. The food allergy were ongoing. The patient reported experiencing no side effects after first dose of Shingrix. The reporter consented to follow up.
This case reported by a other health professional via call center representative and described the occurrence of injection site induration in a 48-year-old female patient who received BOOSTRIX (batch number 9924L, expiry date 14th February 2017). Concomitant products included ENBREL; TWINRIX; TYPHOID; VALTREX and INDOMETHACIN. On 23rd March 2015 13:00, the patient received BOOSTRIX (intramuscular) .5 ml. In March 2015, less than a week after receiving BOOSTRIX, the patient experienced injection site induration, injection site itching, injection site erythema, injection site swelling and injection site warmth. On an unknown date, the outcome of the injection site induration, injection site itching, injection site erythema and injection site warmth were not recovered/not resolved and the outcome of the injection site swelling was not recovered/not resolved. It was unknown if the reporter considered the injection site induration, injection site itching, injection site erythema, injection site swelling and injection site warmth to be related to BOOSTRIX. Additional information: A patient who received BOOSTRIX experienced an indurated, red, and kind of warm injection site the size of 3x5x3 cm. There was a little bit of erythema, little bit of mild swelling, and some itching. All of the patient's vital signs were fine. The nurse will be following up to confirm event resolution.
This non-serious spontaneous case, initially received from other health professional (nurse) on 15-Mar-2018, concerning a 62-year-old, adult, male patient. The patient's historical vaccine included pneumonia vaccine (unspecified date). The patient received other unspecified vaccinations within last 4 weeks (as reported). The patient's current conditions included asthma, wheezing, heart disease and lung disease (unspecified date). The patient was a smoker. On an unspecified date first temperature excursion of the vaccine occurred. On 18-Jan-2018, the patient was administered with AFLURIA (TIV) (dose: 0.5 ml, anatomical location: left arm, batch number: XT59906, expiry date: 06-Jun-2018 and route of administration: not reported) after first temperature excursion. On an unspecified the vaccine was stored out of range for 65 hours and 35 minutes, reaching a highest temperature of 60 degree F which was the fifth (5th) excursion with those vaccines.
Information has been received from a 13 year old female patient with no pertinent medical history, drug reactions or allergies reported who in June 2009, was vaccinated with a second dose of GARDASIL (route and lot # unknown). There was no concomitant medication. The patient reported that since "last 3-5 weeks", on approximately 24-DEC-2009, she was experiencing hair loss and bald spots after receiving the second dose of the vaccine. No lab diagnostic studies performed. The patient sought medical attention at the physician's office. At the time of the report the patient had not recovered. Additional information has been received from a certified medical assistant concerning a 14 year (also reported as 13 year old) old female who on 30-JUN-2009 was vaccinated with the first dose of GARDASIL (Lot number 662404/0312Y) intramuscularly in the left deltoid at 15:37. On 23-JUN-2009, the patient was vaccinated with the first dose of PEDIARIX (Lot number AC52802768A) intramuscularly in the left deltoid at 16:15 and the first dose of MENACTRA (lot number U2815AA) intramuscularly in the right deltoid at 16:15. On 06-OCT-2009, the patient received dose of GARDASIL (lot number 660612/0229X) intramuscularly in the left deltoid at 15:04. There were no illnesses reported at time of vaccination. The patient was seen at the physician on 28-JAN-2010 for hair thinning. The onset of the symptoms was approximately 14-JAN-2010, 1-2 weeks prior to the appointment. On 29-JAN-2010 the laboratory tests were within normal limits except for mean platelet volume 7.2, blood neutrophil count 66% and blood lymphocyte count 25. At the time of report the patient present status was unknown. Additional information was received from the registered nurse who reported that there was no further work up on the patient, so the current status of the patient was unknown. Additional information is not expected.
Pt vomited x 1, diarrhea x 24-36 hours, decreased appetite, fever x 24 hours, decreased urine output, lethargy.
No appetite; Cold when he is typically a warm person; Temperature/Fever; sweated profusely; even the sheets, pillowcase and everything was wet; Flu-like symptoms; Soreness at the Injection Site; This is a spontaneous report from a contactable consumer or other non hcp. A 49-years-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot Number: EN6203), via an unspecified route of administration, administered in Arm Left on 25Feb2021 (at the age of: 49-years-old) at 08:30 or quarter till 9:00 as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications. The patient did not receive any other products. The patient did not receive any other vaccine with in 4 weeks prior to the vaccination. The reporter stated that she want to report a strange reaction, a more intense reaction, than they had anticipated. She states that they both had the vaccine on 25Feb2021. she states that they both had a mild reaction at first with soreness at the injection site and flu like feeling like she did rather go lay on the couch for 2 days than do anything else, type symptoms. reporter stated that the patient developed a more intense and had an extreme reaction, and still had a temperature. The reporter assumed that it was his left arm, since he was right handed. She was not sure if he was still had. The patient went to the hospital ER on Thursday, 04Mar2021, to be attended to and he was still not feeling well, a little better but still not well and they did a urinalysis and imaging of the abdomen, a Covid Test that was negative, Liver Function tests, and quite a few other tests, but the patient elected to go home because they did not find anything. The patient was extremely fit and works out every day and they never expected a reaction like this. He had a high fever that is going up and down, and he sweated profusely even the sheets, pillowcase and everything was wet. He had an erratic and sporadic reaction. On an unspecified date, the patient had no appetite, he did not want to eat and he was cold, when he was typically a warm person. The patient underwent lab tests and procedures which included body temperature with over 102 degrees on 02Mar2021 over 102 degrees Fahrenheit, imaging procedure with unknown result, liver function test with unknown result and sars-cov-2 test with negative on and urine analysis with unknown result. The outcome of the pyrexia, sweated profusely; even the sheets, pillowcase and everything was wet, no appetite, Cold when he is typically a warm person was recovering and Flu-like symptoms was not recovered and Soreness at the Injection Site was unknown.  No follow-up attempts are possible. No further information is expected.
Birth defect (microtia and atresia) from my son, born 11/14/2022 resulting in conductive hearing loss on the right side
Due to patient's age she should have been administered a Pediatric dose of Hepatitis A but instead she was administered a Adult dose of Hepatitis A vaccine. Patient did not have any symptoms due to this mix up.
4:00 Pt. states feels dizzy B/P 130/104, 02 sat 96% P 86, states has  not eaten or had water. 4:30 B/P 128/99 02 98% P 88, no longer feeling dizzy has left cllnic post vaccine area.
Pt recvd vax & w/in 1 min, exp a transient shock-like episode (stopped breathing, limp, turned blue);  Episode lasted 1 1/2 mins; pt recovered;
This spontaneous report as received from a physician refers to an unspecified number of female patients of unknown age and gender. This is part of a Market Research. On unknown dates, the patients were vaccinated with GARDASIL (route, dosage schedule, lot # and expiration date were not provided). On unknown dates, several women faint or pass out in the minutes after receiving GARDASIL. At the time of report, the outcome of syncope and dizziness was reported as recovered as they all were fine. The physician also added that he had never seen this with boys receiving GARDASIL. The reporter considered the events to be related to the suspect therapy. Additional information is not expected as the reporter refused additional contact.
shingles or herpes zoster; This spontaneous report was received from a lawyer an the patient regarding a case in litigation and refers to a male patient (pt) of unspecified age. No information was provided regarding the patient's medical history, concurrent conditions, previous drug reactions, allergies and concomitant medications.  In or about 2013, the patient was inoculated by a healthcare provider with zoster vaccine live (ZOSTAVAX) (strength, dose, route of administration, anatomical location, lot number and expiration date were not reported) for the long-term prevention of herpes zoster or shingles.  On an unspecified date, subsequent to zoster vaccine live (ZOSTAVAX) inoculation, the patient experienced shingles or herpes zoster and was hospitalized; he received unspecified treatment for the event. It was stated that as a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; significant medical and related expenses as a result of these injuries, including but not limited to costs for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages.  At the reporting time, the patient had not recovered from the event and it was considered it to be related to zoster vaccine live (ZOSTAVAX).
Patient presented to the ED for acute pulmonary embolism and was subsequently hospitalized for end of life care. Patient died on 12/31/2021. This visit was within 6 weeks of receiving covid vaccination.
tingling in the throat, seen & cleared by EMS; B/P-151/94, P-88
No adverse event; adult received dose from a vial indicated for 6-11 years; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (adult received dose from a vial indicated for 6-11 years) and NO ADVERSE EVENT (No adverse event) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR6965B) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Pfizer vaccine (Two primary doses of vaccine). Past adverse reactions to the above products included No adverse event with Pfizer vaccine.    On 15-Sep-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 15-Sep-2022, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (adult received dose from a vial indicated for 6-11 years). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (adult received dose from a vial indicated for 6-11 years) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (adult received dose from a vial indicated for 6-11 years).    Concomitant product use was not provided by the reporter.  The health department brought a vial and said it was a 5-dose Moderna booster. The health department did not specify the age group. The label said booster doses only. The nurse stated the clinic assumed it was the bivalent vaccine for 18 plus. However, the vial was for 6 to 11 years.  Treatment information was not provided.
Pt recvd vax & 2 days later exp neck pain, h/a, dizziness, inability to raise rt arm, constipation & very high blood sugar;
feels off balance; felt discombobulated; can't walk right; feels dizzy; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of BALANCE DISORDER (feels off balance), CONFUSIONAL STATE (felt discombobulated), GAIT DISTURBANCE (can't walk right), DIZZINESS (feels dizzy) and INJECTION SITE PAIN (sore arm) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030L20A and 010M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included CANNABIDIOL (CBD OIL), AMLODIPINE and BUSPIRONE for an unknown indication.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Feb-2021, the patient experienced BALANCE DISORDER (feels off balance), CONFUSIONAL STATE (felt discombobulated), GAIT DISTURBANCE (can't walk right), DIZZINESS (feels dizzy) and INJECTION SITE PAIN (sore arm). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, BALANCE DISORDER (feels off balance), CONFUSIONAL STATE (felt discombobulated), GAIT DISTURBANCE (can't walk right), DIZZINESS (feels dizzy) and INJECTION SITE PAIN (sore arm) outcome was unknown.
Immediately got pain in the arm and sore; Injection site warm to the touch; Injection site swollen; Injection site itch; Felt tired; This spontaneous case was reported by an other health care professional and describes the occurrence of INJECTION SITE PAIN (Immediately got pain in the arm and sore), INJECTION SITE WARMTH (Injection site warm to the touch), INJECTION SITE SWELLING (Injection site swollen), INJECTION SITE PRURITUS (Injection site itch) and FATIGUE (Felt tired) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy and Drug allergy (Allergic to ceclor, Levaquin and monested.).    On 02-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Jan-2021, the patient experienced INJECTION SITE PAIN (Immediately got pain in the arm and sore), INJECTION SITE WARMTH (Injection site warm to the touch), INJECTION SITE SWELLING (Injection site swollen), INJECTION SITE PRURITUS (Injection site itch) and FATIGUE (Felt tired). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, INJECTION SITE PAIN (Immediately got pain in the arm and sore), INJECTION SITE WARMTH (Injection site warm to the touch), INJECTION SITE SWELLING (Injection site swollen), INJECTION SITE PRURITUS (Injection site itch) and FATIGUE (Felt tired) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided.  Treatment includes pain killers for 2 days.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
Patient was seen by his PCP and received age related vaccines or Tdap and meningitis (right arm), Pfizer COVID (given the 12 year old dose) and HPV vaccine (left arm).  Within minutes of receiving the vaccine, he developed a large erythematous wheal that progressed to vesicles on the hive, which progressed over minutes to hours, which bursts and left with open sore that eventually dried and is now left with crusting wound with granulation tissue.  He had no systemic symptoms with this reaction.
Fever and headache that would not go away with medication. Dizziness. Given 1000 mg of Tylenol.
Slight fever, severe chills and shaking to the bone where whole body tightens. Took 2 alka-seltzer plus cold and flu evervescent  tablets. Waiting to see if works.